Lex­eo Ther­a­peu­tics and Abi­vax seek Nas­daq list­ings in shrink­ing pre-Thanks­giv­ing win­dow for biotech IPOs

The gene ther­a­py start­up Lex­eo Ther­a­peu­tics and in­flam­ma­to­ry dis­ease biotech Abi­vax filed pa­per­work to go pub­lic Fri­day af­ter­noon, as the pre-Thanks­giv­ing IPO win­dow shrinks and a gov­ern­ment shut­down looms.

New York-based Lex­eo and Paris-based Abi­vax would join about a dozen oth­er drug de­vel­op­ers in go­ing pub­lic this year, aim­ing to trade on the Nas­daq un­der the tick­ers $LX­EO and $AB­VX, re­spec­tive­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER